The European Commission (EC) has authorised the marketing of Bavarian Nordic's Vimkunya - the first chikungunya vaccine ...

The US Centers for Disease Control and Prevention is currently investigating five hospitalizations that occurred in people ...

Five people have been hospitalized with cardiac and neurological symptoms after getting the chikungunya vaccine.

Bhopal: Health authorities in Bhopal have intensified their monitoring and preventive efforts following a roughly 10% rise in ...

If granted, IXCHIQ® will become the first vaccine against the chikungunya virus (CHIKV) available in the EU for adolescents 12 years of age and ...

Five older adults hospitalized after receiving chikungunya vaccine, prompting CDC investigation. Few adverse reactions reported in clinical trials.

Hyderabad: Biological E. Limited has announced a strategic partnership with Bavarian Nordic A/S to expand access to Bavarian ...

Two years on, Bavarian Nordic’s $380 million vaccine M&A move appears to be paying off. | Valneva may have won the ...

Hyderabad-based Biological E. Limited (BE) is partnering with Danish firm Bavarian Nordic to expand access to the latter’s ...

On track for launch in key European markets in the first half of 2025. COPENHAGEN, Denmark, February 28, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced that the European Commission has ...

CNN has reached out to the CDC for comment. Chikungunya virus is typically spread to people through the bite of an infected mosquito. Most adults don’t receive the vaccine; it is sometimes ...

all65 and older, were hospitalized for cardiac or neurologic events following vaccination with IXCHIQ, the only chikungunya vaccine currently licensed in the United States.